Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1‐infected patients without cirrhosis: OPTIMIST‐1, a phase 3, randomized study - Concepedia

Concepedia

Publication | Open Access

Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1‐infected patients without cirrhosis: OPTIMIST‐1, a phase 3, randomized study

DOI Full Paper Access

189

Citations

19

References

2016

Year

Paul Y. Kwo, Norman Gitlin, Ronald Nahass, David Bernstein, K. Peter Etzkorn, Sergio Rojter, Eugene R. Schiff, Mitchell Davis, Peter Ruane, Ziad Younes,

Abstract

Simeprevir+sofosbuvir for 12 weeks is highly effective in the treatment of HCV GT1-infected patients without cirrhosis, including those with Q80K. (Hepatology 2016;64:370-380).

References

	Year	Citations

Page 1